For instance, in the AURELIA study involving platinum-resistant patients, tumor tissue demonstrated a 3.2-fold increase in FGF2 mRNA expression, while the combination of FGFR inhibitors raised the ORR to 27% (Heublein et al., 2024). The gene discussed is FGF2; the disease is neoplasm.